After a median follow-up of 50 years ( IQR 30-71 ) , 40 women in the anastrozole group ( 2 % ) and 85 in the placebo group ( 4 % ) had developed breast cancer ( hazard ratio 047 , 95 % CI 032-068 , p < 00001 ) .